sult in functional derangement of the peritoneal membrane in long-term PD.
PERITONEAL DIALYSIS WITH GLUCOSE-CONTAINING DIALYSIS SOLUTIONS
Conventional dialysis solutions contain a high concentration of glucose. The most commonly used glucose concentrations are 4.25%,2.5%, and 1.5%. After 6 hours of dialysis, approximately 70% of the glucose is absorbed from the peritoneal cavity and approximately 30% of the initial amount of glucose remains in the dialysate regardless of the initial glucose concentration (12) . After 4 hours dwell, the ratio of the final dialysate glucose concentration to its initial value (D4/Do) is approximately 0.37 (13) for a dialysis solution containing 2.5% glucose, and, after 6 hours dwell, D6/Do is approximately 0.30 (14) for a dialysis solution containing 4.25% glucose. The peritoneum is therefore exposed to dialysis solutions containing glucose above 450 mg/dL for 24 hours each day for years. Continuous glucose load during PD is well known to be responsible for metabolic derangements such as hyperglycemia, hyperinsulinemia, aggravation of glucose intolerance, lipid abnormality, and obesity (15) . An unphysiologic ally high concentration of glucose is also known to be related to altered peritoneal cell biology (16) (17) (18) (19) .
STRUCTURAL AND FUNCTIONAL ALTERATIONS OF THE PERITONEAL MEMBRANE IN PERITONEAL DIALYSIS WITH GLUCOSE AS OSMOTIC AGENT
The normal peritoneal membrane is covered with a single layer of mesothelial cells. Submesothelial space is a layer of areolar tissue composed of welloriented bundles of collagen fibers a nd retiform elastic laminae in a ground substance matrix (20) . Various changes to mesothelial cells from reactive hyperplasia, that is, increased numbers of cells per unit area to complete denudation were reported from peritoneal biopsy samples in long-term PD patients (21) . Significant morphological alterations were also noted in the basement membrane of the mesothelium and stromal blood vessels (1, 3, 22) . After several months on CAPD, peritoneal biopsy samples showed reduplication of the basement membranes of the mesothelial layer and the microvasculature of submesothelial stroma in non diabetic patients (21) . In diabetic patients, reduplication of basement membrane was observed in peritoneal capillaries and not in mesothelial area at the beginning of CAPD; but after several months of CAPD, reduplication was observed in both sub mesothelial and capillary basement membranes in the same patients (21) . These finding are similar to changes observed in diabetes mellitus. Increased vascular permeability is an early characteristic of vascular dysfunction in diabetic complications (22) .
The peritoneal membrane becomes hyperpermeable with time on dialysis (23) (24) (25) . As transperitoneal transport of small solutes such as glucose and creatinine increases, the glucose concentration gradient between dialysate and blood decreases faster, and as a consequence, ultrafiltration volume decreases. Loss of ultrafiltration is an important cause of CAPD technique failure. Glucose is believed to be the major pathogenic factor for increasing hyperpermeability of the peritoneal membrane (26) and abnormal water transport (27) . Continuous exposure to high glucose and diabetic change in the peritoneum are, therefore, closely related to membrane hyperpermeability in long-term PD.
AGEs AND
DIALYSIS
Hyperglycemia is the most important pathogenic factor for diabetic complications (2) . In high glucose conditions, protein is non enzymatically glycated. Cross-linking, polymerization, and dehydration of glycated proteins result in irreversible advanced glycosylation end-products (AGEs) (11, 28) , which have been shown to be responsible for diabetic complications and aging (3, 10, 11) .
AGEs are excreted mainly through the kidneys, and the serum level of AGEs increases as the glomerular filtration rate decreases (4, 29) . Pentosidine (15) is the most widely studied AGE to date. The protein-bound form that is, large molecular weight pentosidine consists of more than 95% total pentosidine (6,7). Neither hemodialysis nor PD affects the serum level of the protein-bound form of pentosidine (6, 7) . Despite continuous glucose loading in PD, the serum level ofpentosidine is significantly lower in PD patients compared with patients on conventional hemodialysis (6), or it is similar between the two dialysis therapies (7, 30) .
Dialysate AGEs contained a high proportion of high molecular weight AGE proteins, and the concentration of these AGE proteins was the same as in serum (31) . Interestingly, concentration of AGEs was significantly higher in dialysate than in serum when both dialysate and serum concentrations of AGEs were standardized with their protein concentrations (6, 7) . Furthermore, peritoneal clearance of the albuminbound form ofpentosidine exceeded the clearance of free albumin (7) , and the dialysate level of glycated albumin was higher than the serum level of glycated albumin (32) . Moreover, peritoneal concentrations of pentosidine were significantly higher in PD patients compared with hemodialysis patients, while serum concentrations were significantly lower in PD patients. Pentosidine concentrations in skin were simi lar in PD and hemodialysis patients. These findings significantly higher dialysate concentration of AGEs compared with serum concentration in PD patients, significantly higher peritoneal clearance of albuminbound AGEs than free albumin, and increased peritoneal concentration ofpentosidine -suggest either intraperitoneal formation (6), or facilitated diffusion, or active transport of AGEs across the peritoneum (6, 7, 32) .
Miyata et al (33) and Weiss et al (34) reported that the accumulation of AGEs is not related to the level of blood glucose but is associated with increased oxi dative stress (34) and/or carbonyl stress (35) related with PD. AGEs induce oxidative stress through chemi cal and cellular mechanisms, and oxidative stress causes accelerated formation of AGEs (34) . In PD, carbonyl compounds, derived from uremic circulation, and PD solution, containing high glucose and glucose degradation products, are overloaded, and increased carbonyl stress may not only modify peritoneal matrix proteins and alter their structures, but also react with peritoneal cell surface proteins and initiate inflammatory responses (35) .
Recently, the Amsterdam group (36) reported that pentosidine concentration in peritoneal effluent was higher in PD patients with ultrafiltration failure when compared with patients recently started on PD. Pentosidine level in effluent was directly correlated with duration of PD, and it decreased after use of non glucose dialysate in the same patients (36) . These results suggest that long-term exposure to high glucose is important for peritoneal formation and accumulation of AGEs and impaired ultrafiltration.
PERITONEAL ACCUMULATION OF AGEs
AGEs accumulate mainly in long-lived structural proteins such as collagen, elastin, and myelin; they show characteristic brown pigmentation and fluorescence; and they participate in further proteinprotein cross-linking (37) . Various gross and histopathological findings -such a s a peritoneum that is dry, light brown in color, wrinkled, thickened, leath ery, or tanned (38) ; disorganization of collagen fibers in submesothelial space (39) ; and reduplication of basement membrane in mesothelium and stromal blood vessels (20, 21, 40, 41) -are diabetic complications associated with high glucose levels. In CAPD, continuous exposure of the peritoneum to dialysis solutions containing high glucose may enhance intra peritoneal formation and accumulation of AGEs. Accumulations of AGEs were reported in the mesotheliallayer and submesothelial space of the peritoneum in non diabetic patients after 3 months of PD, while no staining was noted at the beginning of PD in the same patients (8) . Accumulation of AGEs was also noted in the mesothelial layer, submesothelial space, and vascular walls in the peritoneum in both non diabetic and diabetic patients on PD for more than 3 years (8).
Nakayama et al (9) reported positive correlation of the peritoneal accumulation of AGEs and peritoneal permeability. Immunohistochemistry using monoclonal anti-AGE antibody against AGE bovine serum albumin revealed weakly positive staining at the connective tissue, mesothelial layer, and/or submesothelial vascular wall in peritoneal biopsy samples obtained during peritoneal catheter insertion (group 1), moderately positive staining in connective tissue and vascular wall in patients on CAPD for approximately 3 years (group 2), and moderate-to-strong positive staining in mesothelial, vascular wall, and connective tissue in patients on CAPD for approxi mately 7 years (group 3) (9). The peritoneal perme ability to both small molecular weight solutes and large molecular weight solutes was the highest in group 3 and lowest in group 1 (9) .
To evaluate the relationship between peritoneal accumulation of AGEs and peritoneal membrane function with time on CAPD, we performed peritoneal biopsy in 19 patients at the time of catheter insertion (n = 12) or catheter removal (n = 7; duration of PD: 19 months -96 months) owing to ultrafiltration failure, or exit site infection, or both. Peritoneal equilibration test data from one month before and after peritoneal biopsy was used to assess peritoneal membrane characteristics. On linear regression analysis, peritoneal accumulation of AGEs increased with time on CAPD and with the number of peritonitis episodes, but no statistical difference was found. Peritoneal accumulation of AGEs directly correlated with the dialysate-to-plasma ratio of creatinine (D4/P 4 creatinine) after 4 hours dwell and sodium (D1/P 1 sodium) after 1 hour dwell, and inversely correlated with drain volume and glucose concentration ratio in dialysate at 4 hours of dialysis versus time 0 (D4/Do glucose). These data suggest that increased peritoneal accumulation of AGEs with time on CAPD may be caus ally related with the increased peritoneal membrane permeability to small solutes and the decreased ultrafiltration observed in long-term PD patients.
STRATEGIES TO MODIFY AGE-RELATED COMPLICATIONS
As blood-glucose c ontrol is important in preventing or delaying the onset and progression of diabetic complications, the use of non glucose dialysis solutions such as icodextrin (36) , glycerol, or amino acids is the best way to avoid AGE-related complications in PD.
Aminoguanidine inhibits formation of AGEs and protein cross-linking in vitro. Administration of aminoguanidine to rats prevented diabetes -induced formation of AGEs and cross-linking of arterial wall connective tissue protein in vivo (42) and prevented an increas e in vascular permeability in aorta, skin, intestine, heart, vena cava, and brain after exogenous injection of AGE (10) . In experimental animals, intraperitoneal (IP) injection, for 3 months, of dialysis solutions containing high glucose resulted in increased new blood vessels in submesothelial space, and in accumulation of AGEs in submesothelial space, in capillary walls in both submesothelial space and muscularis layers, and endomesium (43) . Administra tion of aminoguanidine during IP injection of dialysis solutions attenuated the accumulation of AGEs in vascular walls in submesothelial space, muscularis layer, and endomesium in the same study (43) .
Because formation and accumulation of AGEs are enhanced by increased oxidative stress (34) , drugs having antioxidant properties are suggested for pharmacological modulation of AGEs (44) . In addition, carbonyl stress is suggested to be related with the formation and accumulation of AGEs (33) . Reducing carbonyl stress in CAPD by reducing glucose degradation products (35, 45) may also be of help in pre venting peritoneal damage related to AGEs (35, 44) .
CONCLUSIONS
In long-term PD, peritoneal formation and accumulation of AGEs increase and are closely related to increased peritoneal permeability. Use of non glucose dialysis solutions, pharmacological modulation of AGE formation and accumulation, and reduction in carbonyl and oxidative stresses related to uremia, PD, or both, may be of help in preventing structural and functional alterations of the peritoneum and in maintaining peritoneal membrane function.
